Premium
Clinical trial for improvement in metabolic syndrome by Korean Chungkookjang (647.27)
Author(s) -
Byun MoonSun,
Yu OkKyeong,
Kim HyunSuk,
Park TaeSun,
Cha YounSoo
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.647.27
Subject(s) - medicine , overweight , metabolic syndrome , placebo , alkaline phosphatase , creatinine , endocrinology , aspartate transaminase , obesity , lipid profile , anthropometry , creatine kinase , alanine transaminase , crossover study , cholesterol , biology , biochemistry , enzyme , alternative medicine , pathology
In this study, we investigated the effect of Korean trational Chungkookjang compared to placebo on variables of metabolic syndrome in overweight/obese subjects. This double‐blind randomized controlled crossover trial was conducted on 120 overweight/obese subjects; aged 19‐29 years. Each group received either 35 g of Chungkookjang (CK; n = 60) or placebo (PC; n = 60) on a regular daily basis for 12 weeks. After 12‐weeks period, the groups was crossed over. The anthropometric measures, blood pressure, glucose parameter, lipid profile, adipocytokine, and carnitine assay was determined at baseline and 12 week. Also, safety was assessded by measuring total bilirubin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, total protein, albumin, blood urea nitrogen, creatinine, and creatine kinase at baseline and 12 weeks. 24‐hour dietary recalls were collected at the baseline and at the end of the trial. Bodyweight, bodyweight gain, serum insulin , leptin level and energy intake were reduced in the CK group. These results suggested that the supplementation of Chungkookjang may contribute to the reduction of risk factor for metabolic syndrome caused by obesity. Grant Funding Source : Korean Institute of Planning & Evaluation for Technology in Food, Agriculture Forestry & Fisheries